Table 1 List of study agents
Agent name* | Date arm closed | N | Mechanism | AE of special interest |
|---|---|---|---|---|
Remdesivir/Corticosteroid | Backbone | NA | Protide/Immunomodulator | Abnormal liver function |
Razuprotafib (Aerpio) | 2021.03.12 | 22 | Vascular endothelial PTP inhibitor/ activator of Tie-2 | None |
Apremalist (Otezla) | 2021.03.05 | 68 | PDE4 inhibitor | None |
Cenicriviroc | 2021.04.28 | 91 | CCR2 and CCR5 inhibitor | Abnormal liver function |
Icatibant/Firazyr | 2021.04.15 | 96 | Bradykinin inhibitor | None |
Pulmozyme | 2022.01.10 | 39 | Recombinant DNAse | Abnormal liver function, transmission of infectious agent via study drug |
IC14 | 2021.12.03 | 67 | Anti-CD14 antibody | New infections, Eye symptoms |
Famotidine + Celecoxib | 2021.09.02 | 30 | Famotidine: H2 receptor antagonist and inverse agonist Celecoxib: COX-2 inhibitor, NSAID | Famotidine:Thrombocytopenia, sustained ventricular arrythmia Celecoxib: cardiovascular thrombotic events, GI bleeding, heart failure, acute kidney injury, anaphylaxis, Stevens-Johnson syndrome |
Narsoplimab | 2022.09.15 | 68 | IgG4 against MASP-2, an effector enzyme of the lectin pathway of complement | Infusion reactions, anaphylaxis, elevated liver enzymes, infections |
Aviptadil | 2021.06.15 | 52 | Synthetic human vasoactive intestinal peptide | Diarrhea (Grade 3+) |
Cyclosporine | 2022.08.08 | 110 | Calcineurin inhibitor | Infection, hypertension, neurotoxicity, acute kidney injury, abnormal liver function |
Cyproheptadine | 2023.01.04 | 35 | Antihistamine and serotonin antagonist with anticholinergic effects | Delirium or hallucinations, urinary retention, mucous obstruction, ilieus |
